Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Coronaviruses
  4. Fast Track Articles
  5. Fast Track Article
image of Correct Use of HCQ Did Not Cause Extra Fatalities in COVID-19 Infection
file format pdf download PDF

Abstract

A recent study has claimed that nearly 17,000 people in the U.S. and five other countries died prematurely during the early stages of the COVID-19 pandemic due to the compassionate use of hydroxychloroquine (HCQ) for treatment. However, this study's conclusions are contentious due to reliance on flawed data and the neglect of significant evidence supporting HCQ's efficacy in early outpatient treatment. Our critique challenges the validity of the study, highlighting its methodological weaknesses and the confounding factors it overlooked. By reviewing the comprehensive body of scientific literature, we demonstrate that treatment with HCQ, particularly in combination with zinc and antibiotics, consistently yielded positive outcomes, especially in the early stages. This work aims to provide a balanced and objective assessment of HCQ's impact on COVID-19, emphasizing the importance of early intervention and proper dosage.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975327612240902104505
2024-09-16
2024-11-26

  • From This Site

    /content/journals/covid/10.2174/0126667975327612240902104505
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/covid/10.2174/0126667975327612240902104505/BMS-COVID-2024-84.html?itemId=/content/journals/covid/10.2174/0126667975327612240902104505&mimeType=html&fmt=ahah

References

  1. Pradelle A. Mainbourg S. Provencher S. Massy E. Grenet G. Lega J.C. Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: An estimate. Biomed. Pharmacother. 2024 171 116055 10.1016/j.biopha.2023.116055 38171239
    [Google Scholar]
  2. HCQ for COVID-19. Available from: c19hcq.org/
  3. Estimated cumulative excess deaths per 100,000 people during. COVID 2024 19 ••• ourworldindata.org/explorers/coronavirus-data-explorer
    [Google Scholar]
  4. Gautret P. Lagier J.C. Parola P. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 2020 56 1 105949 10.1016/j.ijantimicag.2020.105949 32205204
    [Google Scholar]
  5. Esper R.B. da Silva R.S. Oikawa F.T.C. 2020
  6. Ashraf M.A. Shokouhi N. Shirali E. COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes. MedRxiv 2020
    [Google Scholar]
  7. Huang M. Li M. Xiao F. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. Natl. Sci. Rev. 2020 7 9 1428 1436 10.1093/nsr/nwaa113 34676087
    [Google Scholar]
  8. Guérin V. Lévy P. Thomas J.L. Azithromycin and hydroxychloroquine accelerate recovery of outpatients with mild/moderate. COVID 2020 19
    [Google Scholar]
  9. Derwand R. Scholz M. Zelenko V. COVID-19 outpatients: Early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: A retrospective case series study. Int. J. Antimicrob. Agents 2020 56 6 106214 10.1016/j.ijantimicag.2020.106214 33122096
    [Google Scholar]
  10. Mitjà O. Corbacho-Monné M.B. Ubals M.B. Tebe C. Peñafiel J. Tobias A. 2020. Hydroxychloroquine for early treatment of adults with mild Covid-19: A randomized-controlled trial. Clin. Infect. Dis. 2021 73 11 e4073 e4081 10.1093/cid/ciaa1009 32674126
    [Google Scholar]
  11. Skipper C.P. Pastick K.A. Engen N.W. Hydroxychloroquine in nonhospitalized adults with early COVID-19: A randomized trial. Ann. Intern. Med. 2020 173 8 623 631 10.7326/M20‑4207 32673060
    [Google Scholar]
  12. Hong K.S. Jang J.G. Hur J. Early hydroxychloroquine administration for rapid severe acute respiratory syndrome coronavirus 2 eradication. Infect. Chemother. 2020 52 3 396 402 10.3947/ic.2020.52.3.396 32757497
    [Google Scholar]
  13. Bernabeu-Wittel M. Ternero-Vega J.E. Nieto-Martín M.D. Effectiveness of an on-site medicalization program for nursing homes with COVID-19 outbreaks. J Gerontol A 2021 76 3 e19 e27
    [Google Scholar]
  14. Yu B. Li C. Chen P. Li J. Jiang H. Wang D.W. Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs. Sci. China Life Sci. 2021 64 2 330 333 10.1007/s11427‑020‑1782‑1 32761451
    [Google Scholar]
  15. Ly T.D.A. Zanini D. Laforge V. Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March–June 2020. Int. J. Antimicrob. Agents 2020 56 6 106219 10.1016/j.ijantimicag.2020.106219 33189890
    [Google Scholar]
  16. Ip A. Ahn J. Zhou Y. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study. BMC Infect. Dis. 2021 21 1 72 10.1186/s12879‑021‑05773‑w 33446136
    [Google Scholar]
  17. Heras E. Garibaldi P. Boix M. COVID-19 mortality risk factors in older people in a long-term care center. Eur. Geriatr. Med. 2021 12 3 601 607 10.1007/s41999‑020‑00432‑w 33245505
    [Google Scholar]
  18. Kirenga B. Muttamba W. Kayongo A. Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda. BMJ Open Respir. Res. 2020 7 1 e000646 10.1136/bmjresp‑2020‑000646 32900781
    [Google Scholar]
  19. Sulaiman T. Mohana A. Alawdah L. The effect of early hydroxychloroquine-based therapy in COVID-19 patients in ambulatory care settings: A nationwide prospective cohort study. MedRxiv 2020 10.1101/2020.09.09.20184143
    [Google Scholar]
  20. Guisado-Vasco P. Valderas-Ortega S. Carralón-González M.M. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). EClinicalMedicine 2020 28 100591 10.1016/j.eclinm.2020.100591 33078138
    [Google Scholar]
  21. Szente Fonseca S.N. de Queiroz Sousa A. Wolkoff A.G. Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis. Travel Med. Infect. Dis. 2020 38 101906 10.1016/j.tmaid.2020.101906 33137493
    [Google Scholar]
  22. Cadegiani F.A. Goren A. Wambier C.G. McCoy J. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. New Microbes New Infect. 2021 43 100915 10.1016/j.nmni.2021.100915 34249367
    [Google Scholar]
  23. Simova I. Vekov T. Krasnaliev J. Kornovski V. Bozhinov P. Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health-care workers. New Microbes New Infect. 2020 38 100813 10.1016/j.nmni.2020.100813 33204427
    [Google Scholar]
  24. Omrani A.S. Pathan S.A. Thomas S.A. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine 2020 29-30 100645 10.1016/j.eclinm.2020.100645 33251500
    [Google Scholar]
  25. Agusti A. Guillen E. Ayora A. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial. Enferm. Infecc. Microbiol. Clin. 2020 40 6 289 295
    [Google Scholar]
  26. Su Y. Ling Y. Ma Y. Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China. Biosci. Trends 2020 14 6 408 414 10.5582/bst.2020.03340 33342929
    [Google Scholar]
  27. Amaravadi R.K. Giles L. Carberry M. Hydroxychloroquine for SARS-CoV-2 positive patients quarantined at home: The first interim analysis of a remotely conducted randomized clinical trial. medRxiv 2021 10.1101/2021.02.22.21252228
    [Google Scholar]
  28. Roy S. Samajdar S.S. Tripathi S.K. Mukherjee S. Bhattacharjee K. Outcome of different therapeutic interventions in mild covid-19 patients in a single opd clinic of West Bengal: A retrospective study. medRxiv 2021 10.1101/2021.03.08.21252883
    [Google Scholar]
  29. Mokhtari M. Mohraz M. Gouya M.M. Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting. Int. Immunopharmacol. 2021 96 107636 10.1016/j.intimp.2021.107636 34015598
    [Google Scholar]
  30. Corradini E. Ventura P. Ageno W. Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: Results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). Intern. Emerg. Med. 2021 16 4 1005 1015 10.1007/s11739‑021‑02742‑8 33893976
    [Google Scholar]
  31. Million M. Lagier J. Tissot-DuPont H. Early treatment with hydroxychloroquine and azithromycin in 10,429 COVID-19 outpatients: A monocentric retrospective cohort study. Rev. Cardiovasc. Med. 2021 22 1063 1072 10.31083/j.rcm2203116 34565108
    [Google Scholar]
  32. Sobngwi E. Zemsi S. Guewo M. Doxycycline vs hydroxychloroquine + azithromycin in the management of covid-19 patients: An open-label randomized clinical trial in Sub-Saharan Africa (DOXYCOV). Cureus 2023 15 9 e45619 10.7759/cureus.45619 37868535
    [Google Scholar]
  33. Sawanpanyalert N. Sirijatuphat R. Sangsayunh P. Assessement of outcomes following implementation of antiviral treatment guidelines for COVID-19 during the first wave in Thailand. Southeast Asian J. Trop. Med. Public Health 2021 52 4 572 585
    [Google Scholar]
  34. Chechter M. Dutra da Silva G.M. Costa R.A.P. Evaluation of patients treated by telemedicine in the beginning of the COVID-19 pandemic in São Paulo, Brazil: A non-randomized clinical trial preliminary study. Heliyon 2023 9 4 e15337 10.1016/j.heliyon.2023.e15337 37073324
    [Google Scholar]
  35. Rouamba T. Ouédraogo E. Barry H. Assessment of recovery time, worsening, and death among inpatients and outpatients with COVID-19, treated with hydroxychloroquine or chloroquine plus azithromycin combination in Burkina Faso. Int. J. Infect. Dis. 2022 118 224 229 10.1016/j.ijid.2022.02.034 35227869
    [Google Scholar]
  36. Avezum Á. Oliveira G.B. Oliveira H. Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE–Coalition V): A double-blind, multicentre, randomised, controlled trial. Lancet Reg. Health Am. 2022 11 1 12
    [Google Scholar]
  37. Rathod D. Kargirwar K. Patel M. Kumar V. Shalia K. Singhal P. Risk factors associated with covid-19 patients in India: A single center retrospective cohort study. J. Assoc. Physicians India 2023 71 6 11 12 37355843
    [Google Scholar]
  38. Azhar S. Akram J. Latif W. Effectiveness of early pharmaceutical interventions in symptomatic COVID-19 patients: A randomized clinical trial. Pak. J. Med. Sci. 2024 40 5 800 810 10.12669/pjms.40.5.8757 38827854
    [Google Scholar]
  39. Evaluating the efficacy of hydroxychloroquine and azithromycin to prevent hospitalization or death in persons with covid-19. Patent NCT04358068, 2021
  40. Rodrigues C. Freitas-Santos R.S. Levi J.E. Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: A randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. Int. J. Antimicrob. Agents 2021 58 5 106428 10.1016/j.ijantimicag.2021.106428 34454044
    [Google Scholar]
  41. Atipornwanich K. Kongsaengdao S. Harnsomburana P. Various combinations of favipiravir, lopinavir-ritonavir, darunavir-ritonavir, high-dose oseltamivir, and hydroxychloroquine for the treatment of COVID-19: A randomized controlled trial (FIGHT-COVID-19 study). SSRN Electron J 2021
    [Google Scholar]
  42. Roy-García I.A. Moreno-Noguez M. Rivas-Ruiz R. Efficacy and safety of fixed combination of hydroxychloroquine with azithromycin versus hydroxychloroquine and placebo in patients with mild covid-19: Randomized, double blind, placebo controlled trial. medRxiv 2022 10.1101/2022.04.06.22273531
    [Google Scholar]
/content/journals/covid/10.2174/0126667975327612240902104505
Loading
Correct Use of HCQ Did Not Cause Extra Fatalities in COVID-19 Infection
Bentham Science Publishers ; https://doi.org/10.2174/0126667975327612240902104505
/content/journals/covid/10.2174/0126667975327612240902104505
/content/journals/covid/10.2174/0126667975327612240902104505
Loading

Data & Media loading...

Keywords: early treatment ; efficacy ; meta-analysis ; Hydroxychloroquine ; outpatient ; critique ; treatment delay ; objective assessment ; pre-existing conditions ; COVID-19
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test